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ARTICLE OPEN
Adherence and quality of life in adults and children during 3-
years of SLIT treatment with Grazax—a real life study
Hampus Kiotseridis1, Peter Arvidsson2, Vibeke Backer3,4, Vagn Braendholt5 and Alf Tunsäter1
Respiratory allergic disease represents a global health problem, 30% of the population suffers from allergic rhinoconjunctivitis and
20% suffer from asthma. Allergy immunotherapy induce immunological tolerance and thereby modify the response to allergens
and sublingual immunotherapy (SLIT) offers the possibility of home administration of allergen therapy, but adherence is more
uncertain. The aim of the study was to investigate the adherence with GRAZAX in adults and children ≥ 5 years during three
consecutive years of treatment. This was a non-interventional, prospective, observational, multi-center, open-label study to
investigate adherence, quality of life, safety and tolerability of GRAZAX in adult and pediatric patients in a real-life setting. During
the 3-years study period estimation of adherence was done regularly. Quality of life as well as symptom score was also assessed. In
total, 399 patients (236 adults and 163 children) were included in the study. At baseline, 100% suffered from moderate-severe eyes
and nose symptoms, and 31% had asthma in the grass pollen season. Overall, 55% completed a 3-years treatment period, whereas
37% stopped before end of study and 8% were lost to follow up. After 3 years, the adherence rate decreased from 98.2% (ﬁrst
month), 93.7% (ﬁrst year), 93.2% (second year) and 88.9% (third year) and adverse events were the main reason for pre-term
termination. The study suggests a good adherence to treatment in a real life setting among the patients ﬁnalizing 3-years SLIT
therapy. The treatment was effective both on symptoms and HRQL.
npj Primary Care Respiratory Medicine  (2018) 28:4 ; doi:10.1038/s41533-018-0072-z
INTRODUCTION
Respiratory allergic disease has increased dramatically during the
last 40 years and it now represents a serious health problem
globally.1–3 Up to 30% of the European population suffers from
allergic rhinoconjunctivitis, 20% suffer from asthma and 15% from
allergic skin conditions. By this, allergy is the most frequent
chronic disease in Europe and in the western societies as such.4 Its
negative impact on quality of life, in physical as well as mental
domains, is well documented for children as well as adults.5,6 Of
patients with intermittent allergic rhinitis 79.2% had some
impairment of their professional life and 91.8% of their daily life.7
Treatment with pharmacotherapy, such as antihistamines and
nasal corticosteroids, is effective in reducing symptoms but they
do not address the underlying allergy. Nor do they prevent
disease progression.4,8 Allergy immunotherapy on the other side,
induce immunological tolerance and thereby modify the response
to allergens and the disease.9 Subcutaneous immunotherapy
(SCIT) has been used for decades, whereas a newer form of
administration, Sublingual Immunotherapy (SLIT), has been
launched within the last decade.10 Compared to SCIT with 30 or
more visits to the physician, treatment with SLIT offers the
possibility of home administration, with a reduced use of medical
resources. Health economical studies have also proven GRAZAX,
grass immunotherapy, to be a cost-effective treatment in the
correct patient group.11
Adherence has been extensively discussed in all respiratory
therapy during last years, as it is documented that around half the
prescriptions are not taken as recommended.12 If the prescription
is appropriate, then this may represent a fail by the patients, the
healthcare system and society and the costs are both personal and
economic. Accordingly, adherence with AIT as well as other long-
term therapies have been questioned when it comes to ordinary
clinical practice and the need for collaboration between
healthcare and patient is important for a successful outcome.13
Immunotherapy is unlike other treatments a therapy with
preventive potential, if it is taken as recommended.14 Data with
GRAZAX in Sweden during one year of treatment showed
promising results with acceptable adherence levels.15 However,
that study duration was only 1 year, and there is no data regarding
the whole treatment period of 3 continuous years. In a study
based on prescription data of 706 patients receiving pollen SLIT
16% got prescription for 3 years of treatment or more.16 In a
retrospective anonymous analysis of 123 SLIT patients (trees mix,
grass pollen, and house dust mite—drops or tablets) it was found
that 61% of the patients fulﬁlled 3 years of treatment.17 Another
retrospective study of 142 SLIT-patients (Rhinitis because of
allergy to house dust mites) showed that 46% fulﬁlled their
treatment.18
Data from big, randomized, double-blind, placebo-controlled
trials have shown that GRAZAX clinically signiﬁcant improves
quality of life. However, there is very limited data regarding quality
of life in a real-life setting. The aim of the study was to investigate
the adherence with GRAZAX treatment in adults and children≥ 5
years followed for a period of 3 consecutive years. Furthermore, to
evaluate how many patients complete GRAZAX treatment and
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lastly to assess the efﬁcacy according to symptoms and quality of
life (HRQL) in a real-life setting.
RESULTS
In total, 399 patients (236 adults: ≥15–67 years and 163 children:
5–≤15 years) were included in the study. The 50 participating
investigators from Denmark and Sweden enrolled between 1–26
patients per investigator. In total 243 (60.9%) from Sweden, 102
(62.6%) children and 141 (59.7%) adults. The corresponding
ﬁgures for Denmark 156 (39.1%) in total, 61 (37.4%) children and
95 (40.3%) adults. The subject demographic values at baseline are
summarized in Table 1.
Allergy history
Patients clinical signs of allergy and main reasons for rhinocon-
junctivitis are summarized Table 1. It was allowed to ﬁll in a
maximum of two main reasons. 68.9% have more than one allergy.
The second most occurring allergy, after grass pollen allergy,
causing rhinoconjunctivitis for both children and adult is birch
pollen allergy. 31.3% had a grass pollen induced asthma.
Symptoms from eyes and nose were mainly moderate-severe at
baseline. For the patients with asthma, most patients had mild-
moderate symptoms. Many patients (57.3%) had general symp-
toms such as tiredness. Symptomatic medication used at grass
pollen season previous to start of GRAZAX treatment were used in
almost all patients (99%). Most common were oral antihistamines,
used by 96% and nasal steroids (63%), After 3 years of treatment
14% did not use any symptomatic medication (Table 2).
Adherence
Of 399 enrolled patients 220 (55%) completed 3 years of
treatment. Of the children, 69% completed the 3-year treatment
period. The most common reason for discontinuation was adverse
event. 65% of discontinuation was made shortly after visit two and
three. The registered cause of discontinued treatment is shown in
Table 3.
Most of the patients, in the intention to treat population, took
their Tablets 6–7 times per week. 94.9% after 1 month, 89.3% at
visit 3, 91.3% at visit 4, and 81.3% after third grass pollen season.
In the pediatric group, the adherence was higher. 97.1% after
1 month, 92.1% after ﬁrst season, 92.0 after 2 years and 83.1%
after 3 years of treatment, Oversight is the most common reason
for not taking their tablets as agreed upon.
For patients with 3 years of treatment (per protocol population)
the adherence was even higher, starting with 98.2% of adherence
during the ﬁrst month, 93.7% at visit 3, 93.2% at visit 4, and ending
with 88.9% after third visit.
68.7% of the patients (ITT) were offered a tool for adherence by
the Investigator at visit 1 but a minority of patients used any.
Medimemo is the most offered and used from visit 1 until visit 2. If
any adherence tools are used later during the treatment this is
most often “other”, e.g., reminder on mobile phone.
Allergy symptoms
A description of allergy symptoms by visit is presented in Fig. 1. A
statistical signiﬁcant reduction can be seen for all speciﬁed
symptoms. The largest changes were seen in rhinoconjunctivitis
symptoms (eyes and nose) and for general symptoms where
tiredness is an example of general symptoms. A reduction in
asthma and skin symptoms were also seen. Only few patients
speciﬁed other symptoms.
The result on the VAS scale question: “How have your allergy
symptoms been last GPS during peak” also showed an improve-
ment after ﬁrst grass pollen season that increases during
treatment. A mean at baseline of 7.67 were reduced to 3.86 after
ﬁrst season, 2.9 after second and 2.72 after 3 years of treatment
season. In total, a reduction of 5.16 in all 3 years (p < 0.01).
Table 1. Demograﬁc values at baseline and clinical signs of grass
allergy and number of single grass/multiallergic
Total (n= 399) Child (n= 163) Adult (n= 236)
Age (yrs) 24.2 (15.1) 10.6 (2.9) 33.6 (12.8)
17.7 (5.0; 67.3) 10.8 (5.0; 15.2) 34.1 (15.4; 67.3)
n= 399 n= 163 n= 236
Gender
Male 241 (60.4%) 117 (71.8%) 124 (52.5%)
Female 158 (39.6%) 46 (28.2%) 112 (47.5%)
Country
Sweden 243 (60.9%) 102 (62.6%) 141 (59.7%)
Denmark 156 (39.1%) 61 (37.4%) 95 (40.3%)
Clinical signs of grass allergy
Rhinitis 383 (96.0%) 154 (94.5%) 229 (97.0%)
Asthma 125 (31.3%) 48 (29.4%) 77 (32.6%)
Conjunctivitis 363 (91.0%) 153 (93.9%) 210 (89.0%)
Atopic
eczema
40 (10.0%) 14 (8.6%) 26 (11.0%)
Other 86 (21.6%) 26 (16.0%) 60 (25.4%)
Single grass/multi allergic
Single grass 124 (31.1%) 58 (35.6%) 66 (28.0%)
Multi allergic 275 (68.9%) 105 (64.4%) 170 (72.0%)
For categorical variables n (%) is presented
Table 2. Symptomatic medication during the study for those fullﬁlling
the treatment
Variable Visit 1 (n=
220)
Visit 3 (n =
220)
Visit 4 (n=
220)
Visit 5 (n=
220)
None 1 (0.5%) 13 (5.9%) 27 (12.3%) 33 (15.0%)
Oral antihistamines 215 (97.7%) 188
(85.5%)
170
(77.3%)
166
(75.5%)
Oral corticosteroids 13 (5.9%) 2 (0.9%) 5 (2.3%) 3 (1.4%)
Oral leukotriene
antagonists
9 (4.1%) 6 (2.7%) 6 (2.7%) 5 (2.3%)
Oral other 1 (0.5%) 0 (0.0%) 0 (0.0%) 3 (1.4%)
Nasal antihistamines 38 (17.3%) 27 (12.3%) 15 (6.8%) 17 (7.7%)
Nasal corticosteroids 139 (63.2%) 83 (37.7%) 76 (34.5%) 65 (29.5%)
Nasal chromones 4 (1.8%) 3 (1.4%) 1 (0.5%) 2 (0.9%)
Nasal other 6 (2.7%) 7 (3.2%) 3 (1.4%) 7 (3.2%)
Eye antihistamines 121 (55.0%) 74 (33.6%) 61 (27.7%) 64 (29.1%)
Eye corticosteroids 13 (5.9%) 3 (1.4%) 5 (2.3%) 5 (2.3%)
Eye chromones 35 (15.9%) 10 (4.5%) 14 (6.4%) 13 (5.9%)
Eye other 19 (8.6%) 12 (5.5%) 5 (2.3%) 10 (4.5%)
Inhalation
corticosteroids
58 (26.4%) 49 (22.3%) 46 (20.9%) 40 (18.2%)
Inhalation ß2 agonists
(short acting)
56 (25.5%) 34 (15.5%) 38 (17.3%) 37 (16.8%)
Inhalation ß2 agonists
(long acting)
19 (8.6%) 10 (4.5%) 17 (7.7%) 13 (5.9%)
Inhalation other 1 (0.5%) 7 (3.2%) 6 (2.7%) 7 (3.2%)
Injection
corticosteroids
17 (7.7%) 1 (0.5%) 1 (0.5%) 0 (0.0%)
Injection other 1 (0.5%) 1 (0.5%) 0 (0.0%) 0 (0.0%)
For categorical variables n (%) is presented
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Quality of life in adults
Mini-RQLQ showed an improvement when compared to visit 1
(baseline) both for measurements during GPS and at the
scheduled visits. Patient scores were lower after GPS than during
GPS. The overall score improved from 2.92 at baseline to 1.45 after
1 year, 1.04 after 2 years, and 0.88 after 3 years of treatment. All
the domains improved signiﬁcantly during the 3 years of
treatment (p < 0.01) (Fig. 2).
As concerns Mini-AQLQ there were improvement when
comparing to visit 1 (baseline) both for measurements during
GPS and at the scheduled visits between GPS (p < 0.01) but not for
GPS 2 (p = 0.06 and GPS 3 (p = 0.49).
There was a good correlation between assessment during
pollen season and retrospective assessment although the retro-
spective assessment showed a tendency to underestimate the
problems after the season for PADQLQ, RQLQ (p < 0.05) but not
the AQLQ. ICC was for PADQLQ; AQLQ and RQLQ 0.56612, 0.73279,
and 0.36636, respectively.
Quality of life in children (aged 5–<15 at start)
PADQLQ showed statistically signiﬁcant improvement when
comparing to visit 1 (baseline) both for measurements during
GPS and at the scheduled visits between GPS (Fig. 3).
The total score improved from 2.31 to 1.06 after ﬁrst year, 0.803
after second year and 0.733 after 3 years of treatment (p < 0.01).
All domains improved signiﬁcantly during the treatment period
(physical, emotional, and practical). The difference of 1.6 exceeded
well beyond 0.4, which is considered as clinical relevant, for the 3-
year treatment period
DISCUSSION
SLIT has been shown in clinical RCT studies to be effective with
usually mild side effects. Adherence is an important issue when
treating with a tablet taken at home compared to SCIT given at
the ofﬁce. Especially for a long treatment, where it is known that
adherence can be challenging. No long-term study has investi-
gated the adherence over 3 years of GRAZAX treatment on
patients with rhinitis and/or asthma in ordinary clinical practice.
This study therefore adds new valuable real-life data to the
existing large pool of data from clinical studies.
The study demonstrated that at least 55% of enrolled patients
(220/399) completed 3-years treatment in ordinary clinical
practice. Of patients completing treatment, 85% stated they took
GRAZAX 6–7 times/week. A recent real-life analysis of SLIT-
patients, with rhinitis because of house dust mites allergy, showed
that 46% fulﬁlled treatment.18
Adherencerate to SLIT vary a lot in literature. One reason for this
could be the different ways to select patients. Some studies in this
ﬁeld are based on prescriptiondata and others on retrospective
analysis.16–18 In some studies the studypatiens get SLIT with
different allergens and in different administrations (drops or
tablets).17 That makes it difﬁcult to compare the adherence data
between studies.
Adherence to prescribed treatment for chronic disease is
generally low. Adherence results vary between different studies.
For comparison with the results of this study can be mentioned
that adherence to antihypertensive treatment is set to 64% in a
study from 2008.19 The same study shows that adherence to oral
antidiabetic treatment is 58% and lipid-lowering medication, 51%.
In an asthma study at a pediatric group followed for 2 years the
adherence to inhaled corticosteroids was only 50% after 2 years of
treatment.20 In another study of COPD patients 37% had
suboptimal adherence.21 Adherence is usually studied for a short
Table 3. Cause of discontinued treatment that was registered at each
visit
Reason by last visit
Reason for discontinuation Last visit
Frequency percent (row
percent;
column percent)
1 2 3 4 5 Total
Lost to follow up 0 10 10 9 2 31
0.00 5.59 5.59 5.03 1.12 17.32
0.00 32.26 32.26 29.03 6.45
0.00 16.95 17.24 40.91 12.50
Bad effect 0 4 6 2 2 14
0.00 2.23 3.35 1.12 1.12 7.82
0.00 28.57 42.86 14.29 14.29
0.00 6.78 10.34 9.09 12.50
Poor compliance 2 4 4 2 5 17
1.12 2.23 2.23 1.12 2.79 9.50
11.76 23.53 23.53 11.76 29.41
8.33 6.78 6.90 9.09 31.25
Economical reasons 1 1 0 1 1 4
0.56 0.56 0.00 0.56 0.56 2.23
25.00 25.00 0.00 25.00 25.00
4.17 1.69 0.00 4.55 6.25
Adverse events 17 26 19 2 4 68
9.50 14.53 10.61 1.12 2.23 37.99
25.00 38.24 27.94 2.94 5.88
70.83 44.07 32.76 9.09 25.00
Other 2 6 13 3 2 26
1.12 3.35 7.26 1.68 1.12 14.53
7.69 23.08 50.00 11.54 7.69
8.33 10.17 22.41 13.64 12.50
Not known 2 8 6 3 0 19
1.12 4.47 3.35 1.68 0.00 10.61
10.53 42.11 31.58 15.79 0.00
8.33 13.56 10.34 13.64 0.00
Total 24 59 58 22 16 179
13.41 32.96 32.40 12.29 8.94 100.00
Fig. 1 Allergy symptoms. Allergy symptoms during pollen season at
baseline (visit 1), after 1 year of treatment (visit 3) and after 2 and 3
years of treatment respectivly (visits 4 and 5). All symtoms improved
during treatment including general symptoms
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time in the context of clinical trials. Rarely in a real-life setting that
lasts for 3 years.
According to this real life study, the main reason for not
completing 3 years of treatment were adverse events (38% of
patients discontinuing treatment). Even if the majority of adverse
events were local and mild-moderate, they seem to be bother-
some enough for a signiﬁcant group of patients to stop treatment.
An improved practice how to handle adverse events would
probably improve adherence. This could be improved by clear and
practical information to health care personnel and patients how to
handle adverse events. One observation during this study was that
although 55% on average completed the 3 years of treatment, the
variation in adherence between clinics was great. One explanation
to this could be differences between different clinics as concerns
interest and literacy to handle patients who undergo this kind of
treatment. New initiatives to relieve local side effects in the clinic
could be investigated. Early detection of local symptoms that
could be treated with symptomatic medication could potentially
keep the patients in treatment. In clinical practice experiences
with splitting of tablet, moving to other parts of the vestibulum
and avoiding swallowing the allergen has proved successful.
These methods could be further investigated in an observational
study.
The second reason for discontinuing treatment in this trial is lost
to follow up (17%), this means that health care has lost contact
with the patient. The number of patients continuing treatment in
this group is unknown, but hypothetically the number of patients
completing treatment could be raised if health care had improved
routines for patient follow up.
This study further shows that patient oversight is a minor
problem for not taking GRAZAX. Only a minority, 5%, claimed to
take their GRAZAX tablet 3 times a week or less. Since intake of
tablets were estimated by patients, as this study is not an
interventional trial, the information may be biased. Nevertheless,
the study design with regular contact to health care seems to have
a positive effect on adherence, probably due to increased
understanding from the patient why there is a need to be
compliant with treatment.
The reasons for not completing the 3-year treatment stated by
the patients in this study are in contrast to a recent real-life
analysis showing the reasons for premature cessation of treatment
to be inability to reach the patient (25%), ineffectiveness of
treatment (24%) and the long course (18%).18 In “EAACI Guidelines
on Allergen Immunotherapy: Allergic rhinoconjunctivitis” the
authors found in their review that reported adherence varied
from 18 to 90%.22 The adherence was better in clinical studies
compared to real-life surveys. In that perspectiv our ﬁgures for
adherence seems to be very good. A reason for this could be that
the treatment was carried out in hospitals and in a specialist
reception where the routines with patient education and follow
ups could be expected to be well anchored.
Fig. 2 Health related quality of life in adults. The ﬁrst assessment was done at baseline where patients retrosepectively after pollenseason
assessed the symptoms and burden during the preceding pollenseason. Continously the patients assessed the burden during pollenseason
and after the pollenseason. In A and B RQLQ was used and in C and D the AQLQ was used. In A and C the assessment was done
retrospectively and and in B and D the assessment was done during pollen season
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More children (69%) then adults (45%) remained in treatment
during the study. One reason for this outcome could be that
caregivers, due to concern about children’s health, gives a
reminder to complete treatment. This however, is speculation
and needs further investigation.
Health care is good in offering patients different adherence
tools, 69% were offered a tool at start of treatment. Patients
generally remember to take their GRAZAX as prescribed and
usage of adherence tools seems to have a minor effect according
to this study since only 33–37% uses any tool during treatment.
The same result is previously shown in a one year observational
study performed in Northern Europe.23 In the study patients were
divided in two groups, one using an electronic adherence device
(Memozax) and the other group without any device. The
adherence was good but no difference was seen between the
two groups.
Data from randomized, double-blind, placebo-controlled stu-
dies have shown that GRAZAX clinically signiﬁcant improves
quality of life.23 However, there is very limited data regarding
quality of life in a real-life setting. In this study, the HRQL was
improved both in adults and in children. Not only was the total
score improved but also the different domains (physical, practical,
and emotional).
In the light of allergic disease seen as a systemic disease it
seems important to assess also the non-organ speciﬁc manifesta-
tions. In the present study, the most marked impairment shown
was in the physical functioning. Rhinitis is known to affect
nocturnal sleep and daytime sleepiness. The impaired sleep may
be related to nasal congestion.24 A good sleep is of great
importance because lack of sleep has consequences both for
social functioning and school performance.25 We found that not
only was physical functioning affected but also the emotional
domain was affected. It has been suggested that these effect can
have long term effect of the acquisition of personality and health
behaviors.26 In the study, different QoL questionnaires were used
for adults (mini RQLQ, mini AQLQ) and children (PADQLQ) to
evaluate QoL at baseline, during and after grass pollen seasons
during the study. The reason for choosing this way of evaluation
was ﬁrst to follow the patients during the treatment but also to
see if the patients’ retrospective estimation of symptoms and
quality of life differs from the estimation during pollen season.
Although the AQLQ, RQLQ are validated for symtoms during the
last week, in clinical practice the patients are not seldom assessed
after the the season and we have before during the validation of
the Swedish version of the PADQLQ found good correlation
between the assessment during and after the pollenseason. The
result showed a good correlation between estimation during
pollen season and retrospective estimation after season. although
there was a small tendency to underestimate the problems after
the season.27 Others have also found a fair correlation, but a small
tendency for overestimation,28 In that study, they used the VDS-4
rating scale 0–3(no, mild, moderate, and severe), for symptom
registration and the patients mainly had mild allergic disease wich
could affect the result. if QoL is measured after season doctors
should bear in mind that the symptoms can be both over and
underestimated.
Also, patients’ assessment of allergy symptoms was performed
at baseline and during each season. The following symptoms were
evaluated: asthma, eye symptoms, general symptoms, nose
symptoms, skin symptoms and other. Signiﬁcant changes from
baseline were seen in 5 of the 6 groups. The group not showing
any difference was the group other, however only few patients
registered “other” symptoms. From a clinical point of view the
biggest improvements are as expected in the groups’ eyes, nose
and general symptoms. It was clearly seen that the majority of
patient moves from moderate-severe symptoms to moderate-mild
symptoms, which conﬁrms data from clinical studies.
The positive treatment result is also supported via VAS
measurements. Patients compared their overall allergy symptoms
during pollen peak over the different seasons and highly
signiﬁcant values were seen. Compared to the severity gradings
by Bousquet and coworkers,29 the studypatients symptoms seems
to be moderate/severe at baseline and mild already after one year.
The limit values for MID are met.
However, since no pollen counts were made, a seasonal
variation of pollen count affecting the result can not be excluded.
The beneﬁts of SLIT with tablets in form of reduction of
symptoms and medication are in line with the systematic reviews
concerning the effects of AIT by Dhami et al.30,31 They however
included also subcutaneous therapy, and also treatment with
different sorts of allergens.
CONCLUSIONS
The study demonstrated a good adherence to treatment in a real-
life setting. 55% of enrolled patients and 70% of children
completed 3 years treatment in ordinary clinical practice where
85% took GRAZAX 6–7 times/week.
The treatment was well tolerated and effective both on
symptoms and HRQL.
MATERIAL AND METHODS
Overall study design
This was a non-interventional, prospective, observational, multi-
center, open-label study to investigate adherence, quality of life,
safety and tolerability of GRAZAX in adult and pediatric patients in
a real-life setting in Sweden and Denmark. That means, the
investigator did not affect the selection of patients. They had
already been assessed prior to the study, according to clinical
practice in the Nordic countries, to be suitable for obtaining AIT.
Fig. 3 Quality of life PADQLQ subscales and total score by visit and
during GPS in children. Assessed during pollenseason (a) and as
retrospective estimation after pollenseason (b)
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A desition for Grazax treatment on clinical indication was a
prerequisite for the inclusion in the study.
The assessment was done, after evaluation of the symptoms of
rhinitis and/or asthma and positive outcome of the test for speciﬁc
IgE of grass pollen. In addition to questionnaires, they have also
not been subjected to any form of intervention beyond clinical
practice. The patients did not undergo any training or advice in
addition to that given to all patients receiving this treatment in
the medical care. This is a single study, not part of or a
continuation of an earlier one.
The investigation took place in secondary care units, two allergy
clinics in hospitals in Denmark (Copenhagen and Hilleröd) and
one Specialist reception for children Sweden (Lund).
The study was initiated in 2011 and the patient were followed
up to 36 months, i.e., as long as they were treated with GRAZAX.
When starting a subject on GRAZAX, the investigator planned
5–6 patient visits with approximately 1–12 months in between,
according to clinical practice (see Table 4). If visit 5 (i.e., after third
GPS) coincided with fulﬁlled 3 years of GRAZAX treatment, contact
5 became the ﬁnal visit. However, if the patients started her/his
GRAZAX treatment during springtime 2012, treatment did not
ﬁnish until springtime 2015, which consequently required a sixth
visit.
The assignment of GRAZAX to a patient was not decided in
advance by the protocol but was done according to clinical
practice. Hence, the decision to prescribe GRAZAX was separate
from the decision to include the patient in the study. So, the
inclusion criteria for this study is that the doctor already have
decided Grazax treatment on clinical indication.
All procedures in this study were in accordance with the 1964
Helsinki declaration. The study was approved by the ethics
committee in Lund (2011/508) and patient consent was obtained
prior to the start of the study.
Adherence estimate
At every visit during treatment, patients were asked to estimate
how many tablets he/she did take on average since last visit. If not
taking the tablet the patients were asked about main reason.
Hence—this gave us an oportunity to ﬁnd out not only the level of
adherence but also the reasons for non-adherence. Although this
type of subjective measurement has the risk of overestimating
adherence it has the advantage of being easy to use and does not
interfer much in a real-life setting.18
The patients were also asked whether they have used any tools
(e.g., SMS or Medimemo) in order to remember to take the
GRAZAX tablet. The investigator registered if any tools to help
remembering taking the GRAZAX tablet was offered or not. No
objective measurement of adherence was used in this study.
Quality of life (questionnaires and Visual Analogue Scale, VAS)
Quality of life was assessed for the adults by the well-established
questionnaires mini RQLQ (Rhinitis quality of life questionnaire)
and mini AQLQ (Asthma quality of life questionnaire),32,33
designed for assessments of disease speciﬁc quality of life in
adults for patients with rhinitis and asthma. Both are translated
and validated in Swedish and Danish according to guidelines. For
both questionnaires the minimal important difference (MID) is
considered to be 0.5.
For children, the PADQLQ (Pediatric allergic disease quality of
life questionnaire) was used.
This questionnaire has been developed for assessing the
multisystem effects of allergic disease on HRQL and takes into
account aspects from eyes, nose, lungs, skin, emotions, and
everyday activity.27,34 It has been shown to have a good cross-
sectional and longitudinal validity. It has also been shown to
correlate well with allergic inﬂammation and allergenic load. The
Swedish version also showed good reliability for retrospective
assessment of the QoL during pollen season.6 A difference
between repeated measurements of 0.4 is considered clinical
relevant.
The PADQLQ can discriminate between children with different
degrees of impairment and it has also been shown to be a
sensitive marker for change which makes it a good instrument for
evaluation of therapy. The questionnaire consists of 26 questions
and is self-administered by the children themselves. It takes less
than 10min to answer.
A VAS-scale with a 100mm long scale, from “not bothersome”
to “extremely bothersome” was used. This type of VAS-scale has
been proven to be a useful tool in rhinitis as well as in asthma.29,35
Bousquet showed that patients with a VAS of under 5 cm could be
classiﬁed as mild rhinitis (negative predictive value: 93.5%) and
those with a VAS of over 6 cm as moderate/severe_ rhinitis
(positive predictive value: 73.6%).29 All patients assessed the
following question:” How have your allergy symptoms been last
GPS (Grass pollen season) during peak. This global question
includes all allergy symptoms—also asthma. The MID with VAS in
rhinitis is by Demoly and coworkers calculated to 23 mm in
patients with mild persistent and intermittent allergic rhinitis(AR)
and 22mm in patients with moderate to severe persistent and
intermittent AR.36 Because uncontrolled asthma is a contra-
indication to AIT, the study group contains no uncontrolled
asthmatics as judged by the researchdoctor and speciﬁc asthma
questions are therefor not presented.
Allergy symptoms were graded according to the following:
- mild: transient symptoms, no interference with the patient’s daily
activities
- moderate: marked symptoms, moderate interference with the
patient’s daily activities
- severe: considerable interference with the patient’s daily
activities, unacceptable.
At ﬁnal visit patient and investigator were asked how they
experienced GRAZAX treatment: very satisﬁed, satisﬁed, dissatis-
ﬁed or very dissatisﬁed.
Table 4. Study design
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Screening and ﬁrst
GRAZAX administration.
QoL questionnaire
Follow up adherence,
satisfaction and safety.
(Phone call optional)
Follow up adherence,
satisfaction and safety
QoL questionnaire
Follow up adherence,
satisfaction and safety
QoL questionnaire
Follow up adherence,
satisfaction and safety.
QoL questionnaire
Follow up
adherence,
satisfaction and
safety
Initiation of study App. 1 month after visit 1 After ﬁrst GPS After second GPS After third GPS
(termination of study if
reached 3 yrs treatment)
Final visit, end of
study
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Statistical methods
All measured variables were summarized by descriptive statistics
by visit and change from start of study to each visit if appropriate.
The Population, intention to treat or per protocol, is speciﬁed. All
statistical analysis was nonparametric. Changes over time within
total study group and subgroups were analyzed with Wilcoxon
Signed Rank test for continuous variables and with Sign test for
ordered categorical variables and dichotomous variables.
For comparison between two groups Mann–Whitney U-test was
used for continuous variables, Mantel–Haenszel Chi-square test for
ordered categorical variables, Fisher exact test for dichotomous
variables and Pearson Chi-square test for non-ordered categorical
variables. Spearman correlation coefﬁcient was used for all
correlation analyses. All signiﬁcance tests were two-sided and
conducted at the 5% signiﬁcance level.
Figures over continuous variables over visits and change in
continuous variable from baseline were given as box-plots. Figures
over ordered categorical variables and dichotomous variables over
visits and change in in these types of variables from baseline were
given as bar-charts.
The statistical analyses were performed in SAS 9.3 for Windows
(SAS Institute Inc., Cary, NC, USA).
All data are available from the authors.
Data availability
The datasets generated during and/or analysed during the current
study are available from the corresponding author on reasonable
request.
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